EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Mapping the Global Clinical Landscape of Pharmacological Therapies for Heart Failure With Preserved Ejection Fraction: An Analysis Based on ClinicalTrials.gov (2003–2025)

Yucheng Hou, Jingwei Zhao, Yuqian Tang, Tan Liu, Zhiao Zhang, Ziheng Wang, Han Shen

iMetaMed · 2026-06 · 2 (2)

DOI: 10.1002/imm3.70042 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Heart failure with preserved ejection fraction (HFpEF) accounts for approximately 50% of global heart failure cases yet lacks robust pharmacological options. This analysis maps HFpEF drug trials registered on ClinicalTrials.gov from 2003 to 2025. A systematic search conducted on November 10, 2025, identified HFpEF‐specific drug trials (LVEF ≥ 50%). Data regarding geography, phases, status, time, and drug classes were descriptively analyzed using R (version 4.3.1). Of the 272 trials, 236 qualified, with a notable surge post‐2016 (180 [76.3%]). The majority were U.S.‐led (138 [58.5%]). Phase Ⅱ trials were predominant, comprising 92 trials (39.0%), with 111 trials completed (47.0%) and 36 trials terminated (15.2%). The leading classes of drugs included SGLT2 inhibitors (SGLT2i) and novel/targeted therapies, each represented in 31 trials (13.1%). The period from 2021 to 2025 highlighted a focus on SGLT2i (30 trials, or 27.8%) and an increase in GLP‐1 receptor agonists (GLP‐1RA), following recent approvals (sacubitril/valsartan in 2021; empagliflozin/dapagliflozin in 2022–2023; and finerenone by the FDA in 2025). The expansion of trials post‐2016 favors metabolic and targeted agents. However, attrition rates underscore the need to prioritize phenotype‐specific and combination trials.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →